RESEARCH TRIANGLE PARK, NC— RTI International today announced a strategic collaboration with PierianDx, to help solve the problem of translating complex genomic data into actionable clinical insights to advance precision medicine. The collaboration includes investment and other strategic support to help advance PierianDx’s growth plan.
“Next-generation sequencing is a rapidly evolving scientific field with the potential to inform clinical risk detection, disease identification, and advance prevention and treatment of diseases,” said RTI President and CEO Wayne Holden, Ph.D. “PierianDx’s enabling technology is well aligned with our strategic investment program and RTI’s mission to improve the human condition by turning knowledge into practice.”
Since 2014, PierianDx has focused on providing solutions to accelerate molecular testing to advance precision medicine. The company has built the Clinical Genomics WorkSpace (CGW), one of the most comprehensive clinical genomics platforms in the health care industry that creates streamlined, accurate analysis, interpretations and reporting for clinical labs. By integrating cloud-based software and clinical lab enablement services, the company simplifies the process of translating genomic data into patient-specific diagnosis and treatments. The PierianDx Partner Sharing Network includes 50+ members, including leading academic medical centers, cancer centers and health systems that utilize shared genomic data to target patient-specific diagnosis and treatments for cancers and hereditary diseases.
“Our partnership and investment in PierianDx fits well with our strategic investment program,” said Matt Jenkins, vice president and head of corporate development at RTI. “We are very pleased to be working with the PierianDx team and hope to contribute RTI’s expertise and resources to accelerate PierianDx’s impact and adoption of its genomics platform.”
“We are very excited to collaborate with RTI on numerous fronts and welcome the partnerships and research capabilities they bring in the healthcare sector,” said Rakesh Nagarajan, founder and CEO of PierianDx. “The collaboration between RTI and PierianDx will be a catalyst to advance molecular testing methodologies and precision medicine programs worldwide.”
Terms of the deal were not disclosed.